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Dear Editors-in-chief, 55 
 56 
1  Introduction 57 
Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-58 
term prevention of venous thromboembolism (VTE), and as primary and secondary 59 
prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the 60 
majority of patients requiring chronic anticoagulant therapy were prescribed vitamin 61 
K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. 62 
A requirement for regular monitoring and VKA -drug or-food interactions has meant 63 
that that not all patients that have an indication for anticoagulation have benefitted 64 
from these agents.   To overcome these issues, the direct Xa inhibitor class of direct 65 
oral anticoagulants (DOACs, e.g. apixaban, edoxaban, rivaroxaban) were developed, 66 
which have the advantage of predictable pharmacokinetics and a minimal requirement 67 
for regular monitoring of anticoagulant effect [2].  68 
 69 
A common side effect experienced by patients prescribed rivaroxaban in the landmark 70 
phase III clinical trial evaulating it against warfarin for stroke prophylaxis in AF was 71 
dizziness and headaches.  This occured in up to 1 in 10 patients, and frequently led to 72 
discontinuation of the drug [3]. This side-effect is also being observed, albeit to a 73 
lesser extent, with other DOACs.  At present, it is not known why this occurs, and 74 
why rivaroxaban appears to induce these effects in a greater proportion of patients 75 
than the other DOACs. 76 
 77 
DOACs have recently been reported to have direct cellular effects which appear to be 78 
independent of their ability to inhibit Factor Xa [4].  A non-Factor Xa mediated effect 79 
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on vascular smooth muscle, producing vasorelaxation and a change in blood pressure 80 
in patients prescribed DOACs may explain the observed side effects of headaches and 81 
dizziness.  A potential mechanism may be through facillitation of vascular cell nitric 82 
oxide release.  We therefore hypothesise that direct Xa inhibitors have a direct 83 
vasodilatory effect on blood vessels, possibly through an endothelial cell dependent 84 
mechanism.  85 
  86 
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2  Methods 87 
2.1 Reagents 88 
Rivaroxaban and apixaban were obtained from Carbosynth Ltd. (Berkshire, UK).  89 
Acetylcholine chloride, dimethyl sulphoxide (DMSO), phenylephrine hydrochloride, 90 
and sodium nitroprusside were obtained from Sigma/Aldrich (Poole, UK).  Sprague-91 
Dawley rats used in the ex vivo studies were obtained from Charles River 92 
Laboratories (Kent, UK).  All other chemicals were of reagent grade and obtained 93 
from Fisher Scientific (Loughborough, UK). 94 
 95 
2.2 Ex vivo aortic ring preparation 96 
Thoracic aorta from male Sprague-Dawley rats (180-220 g) were dissected and rings 97 
of 2-3 mm cut and mounted in organ baths filled with warmed (37°C) and gas-98 
equilibrated (95% O2, 5% CO2) Krebs solution containing (in mmol/L) CaCl2 1.6, 99 
MgSO4 1.17, EDTA 0.026, NaCl 130, NaHCO3 14.9, KCl 4.7, KH2PO4 1.18, and 100 
glucose 5. Isometric tension of the rings was measured with force-displacement 101 
transducers (Danish Myo Technology), digitised using PowerLab. A preload tension 102 
of 1.5 g was applied, and the rings were equilibrated for 60 min, followed by 103 
measurement of the concentration-dependent contraction to phenylephrine (10-9 to 10-104 
4 mol L-1) before being washed with fresh Krebs buffer until the tension returned to 105 
that observed prior to the phenylephrine addition. 106 
 107 
2.3 Experimental protocol 108 
Rat aortic rings were precontracted with phenylephrine (10-6 mol L-1) before being 109 
exposed to either rivaroxaban or apixaban (0.01-3 µmol L-1).  The tissue response was 110 
expressed as % relaxation from the maximum tension of the aortic ring prior to any 111 
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drug addition.  The responses of the rings to rivaroxaban and apixaban were 112 
compared to the vehicle (DMSO) which was applied in the same volume as the drug 113 
with the resulting percentage of DMSO ranging from 0.0088 to 0.74% v/v.  In a 114 
second series of experiments rat aortic rings either had their endothelial cells removed 115 
by gentle mechanical abrasion, or were treated with either the competative eNOS 116 
inhibitor L-NG-nitroarginine methyl ester (L-NAME; 100 µmol L-1) or the highly 117 
selective, irreversible inhibitor of soluble guanylyl cyclase (sGC) 1H-118 
[1,2,3]oxadiazol[4,3-a]quinoxalin-1-one (ODQ; 10 µmol L-1) for 10 minutes prior to 119 
the addition of DMSO, rivaroxaban or apixaban (0.01-3 µmol L-1).  Tissue response 120 
was expressed as % relaxation.  121 
 122 
2.4 Statistical analysis 123 
Results are presented as mean ± standard error of the mean (SEM).  Two way 124 
repeated measures analysis of variance with Bonferroni’s correction was used to 125 
compare mean values as appropriate.  Differences were considered significant when 126 
p<0.05.  127 
  128 
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3 Results 129 
3.1 Relaxant effect of rivaroxaban and apixaban on pre-contracted aortic rings 130 
Exposure of phenylephrine pre-contracted rat aortic rings to either rivaroxaban  or 131 
apixaban caused a statistically significant dose-dependent relaxation as compared to 132 
the vehicle DMSO (Fig. 1a).  DMSO at the maximum 0.74% v/v caused a 16.5 ±4.7% 133 
relaxation as compared to 3 µmol L-1 rivaroxaban and apixaban which caused a 134 
47.9±3.7% and 55.5±6.0% relaxation respectively (p<0.05 vs. DMSO). 135 
 136 
3.2 Role of endothelial cells and nitric oxide in the aortic ring relaxant effect of 137 
rivaroxaban and apixaban 138 
The relaxant effect of both rivaroxaban (Fig. 1c) and apixaban (Fig. 1d) was 139 
significantly attenuated by the removal of endothelial cells, with the relaxant response 140 
returned to that observed with vehicle alone.  To determine the role of nitric oxide in 141 
the DOAC-mediated vasorelaxant effect we pharmacologically inhibited either eNOS 142 
or sGC and found that inhibiton of either of these enzymes blocked the relaxant effect 143 
of both rivaroxaban (Fig. 1c) and apixaban (Fig. 1d).  Removal of endothelial cells, or 144 
inhibiton of either eNOS or sGC had no effect on the minor relaxant effect of the 145 
vehicle DMSO (Fig. 1b).   146 
 147 
 148 
  149 
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4  Discussion 150 
 151 
The data presented here demonstrates that the DOACs rivaroxaban and apixaban have 152 
a direct relaxant effect on the vasculature in male Sprague-Dawley rats.  We have also 153 
shown that this vasorelaxant effect of DOACs is both endothelial cell- and NO-154 
dependent.  The proposed mechanism may go some way to explain some of the side 155 
effects attributed to DOACs, including dizziness and headache.  For example, DOAC-156 
induced vasorelaxation of the vasculature may lead to hypotension, producing 157 
symptoms of dizziness as a result of decreased cerebral perfusion.  DOAC-associated 158 
headaches on the otherhand may be attributable to NO-dependent vasorelaxant effects 159 
directly upon cerebral vascular smooth muscle.  Both glyceryl trinitrate and 160 
isosorbide mononitrate are drugs which are well known to produce headaches through 161 
an NO-dependent mechanism [5].  This newly identified DOAC-mediated increase in 162 
NO release from endothelial cells may also contribute to the therapeutic effectivness 163 
of these drugs in VTE and stroke prophalaxis by not only inhibiting factor Xa, but 164 
also increasing NO release to reduce platelet coagulation. 165 
 166 
Previous research has shown that apixaban enhances vasodilation [6].  Although no 167 
direct effect of apixaban on endothelial-mediated NO production was observed, 168 
vasodilation was mediated through protease-activated receptor (PAR)-2  by inhibiting 169 
its desensitization [6].  The group’s results are in contrast to ours, but there are 170 
significant differences in the experimental design between the studies to explain these 171 
observations.  For example, we used aortic rings, wheras Villari et al. used mesenteric 172 
arteries.  Also, our maximum rivaroxaban concentration 3 µM was 3-fold lower than 173 
their lowest concentration of 10 µM [6].  Both we and Villari et al. identified that the 174 
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DMSO vehicle for DOACs has a confounding vasorelaxant effect, and it may be that 175 
this could mask any vasorelaxant effect but because we used lower concentrations of 176 
both rivaroxaban and apixaban we were able to keep the vehicle DMSO percentage 177 
below 1% while maintaining solubility of the DOACs, allowing the direct effect of 178 
DOACs on vasorelaxation to be observed.  179 
 180 
The DOAC-mediated vasorelaxation was found to be both endothelial cell- and NO-181 
dependent.  Although this suggests that it is the endothelial cell NOS that is being 182 
activated by both rivaroxaban and apixaban to induce relaxation, we cannot rule out 183 
that other NOS isoform expressing cells of the vasculature, such as vascular smooth 184 
muscle cells, contribute to the observed DOAC effect [7].  The mechanism by which 185 
DOACs are increasing eNOS activity remains unknown.  However, based on the side 186 
effect profile of DOACs, they are unlikely to be activating receptors that have large 187 
tissue distributions and wide-ranging physiological effects (e.g. muscarinic, 188 
oestrogen, purine, PAR, bradykinin, VEGF, thrombin, histamine) as the side effect 189 
profile associated with such activation would be more obvious from a clinical 190 
perspective. It is interesting to note that apixaban was found to modulate PAR-2 191 
activity on endothelial cells [6]  possibly indicating that this cellular pathway may be 192 
involved in the NO-mediated direct vasorelaxant effect.  The role of PAR-2 in the 193 
DOAC-induced NO-dependent vasorelaxant effect is currently being determined 194 
using a specific pharmacological inhibitor.  195 
 196 
DOACs may also be modifying eNOS activity through affecting its phosphorylation 197 
(eNOS has both stimulatory sites [Ser1177] and inhibitory sites [Thr495] whose 198 
phosphorylation status can affect enzyme activity [8]).  Recently rivaroxaban has 199 
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been shown to increase nitric oxide synthesis in human arterial fibroblasts by 200 
dephosphorylating eNOS at the inhibitory site Thr495, while having no effect at the 201 
stimulatory site Ser1177 [9].  The underlying cellular signalling pathways responsible 202 
for this effect have yet to be elucidated, and whether DOACs can have similar effects 203 
on NOS phosphorylation status in endothelial or vascular smooth muscle cells 204 
remains unknown.       205 
 206 
The concentrations of rivaroxaban and apixaban which caused the most pronounced 207 
NO-mediated vasorelaxation are an order of magnitude higher than those observed 208 
clinically (mean Cmax of rivaroxaban is 0.5 µmol L
-1  and median Cmax of apixaban is 209 
0.37 µmol L-1 [10]), and there may therefore be an argument that these experiments 210 
are not be clinically relevant.  It is therefore important that future experiments are 211 
conducted on human tissue, over a range over doses to confirm clinical relevance.  212 
However, the requirement for these higher concentrations of DOACs to observe an 213 
experimental effect in these short term experiments may be related to their 214 
mechanism of action, for example if DOACs are affecting the endothelial cell eNOS 215 
phosphoylation status as previously shown in atrial fibroblasts [9] higher 216 
concentrations could be required to obtain the level of enzyme dephosphorylation to 217 
cause increased eNOS activity and NO production to mediate vasodilation.  It may 218 
also be related to the difference in responsiveness of rat as compared to human 219 
endothelial cells, for example if the DOAC-induced vasodilation was mediated 220 
through the PAR-2 pathway it may be that the structure/activity relationship between 221 
DOACs and PAR-2 is species dependent. 222 
 223 
11 
 
DOAC-mediated dizziness and headaches are only seen in approximately 10% of 224 
patients, suggesting that there is a particular patient characteristic that may make them 225 
hypersensitive to the vasodilatory effects of DOACs.  The most obvious is that the 226 
pharmacokinetics of DOACs may be altered in the the plasma of patients 227 
experiencing these side effects.  These drugs are metabolised by both CYP-dependent 228 
and independent pathways (www.medicines.org.uk) and a polymorphism affecting 229 
metabolism could result in an increased Cmax high enough to induce vasodilation.  230 
There is also the possibility of patients having polymorphisms in the cellular 231 
pathways which are activated by DOACs to cause vasodilation.  Further studies to 232 
elucidate the specific DOAC-activated pathway that results in increased eNOS 233 
activity could help identify those patients who may go on to experience these side-234 
effects.             235 
 236 
In conclusion, we have identified a novel secondary effect of DOACs to directly 237 
affect endothelial cells and activate the NO-mediated vasorelaxant pathway which if 238 
affecting blood pressure may be the final component of the mechanism by which the 239 
side effects of dizziness and headaches occur.  Identification of the specific 240 
endothelial cell pathways affected by DOACs will allow clinicians to appropriately 241 
optimise anticoagulant treatment and monitoring for patients. 242 
 243 
  244 
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Figure legends 280 
 281 
Figure 1.  Rivaroxaban or apixaban endothelial cell- and NO-dependently 282 
cause ex vivo aortic ring vasorelaxation.  Rivaroxaban and apixaban dose-283 
dependently caused vasorelaxation (A).  Removal of endothelial cells or inhibiton of 284 
either eNOS or sGC significantly inhibited DOAC-mediated vasorelaxation (B-D).  285 
Key: (-E) After removal of endothelial cells, (L-NAME) after eNOS inhibition and 286 
(ODQ) after sGC inhibition.  Data is expressed as mean ± SEM from 4-12 animals; 287 
†p<0.05 vs. DMSO-treated rings; **p<0.01 vs. DOAC alone. 288 
 289 
 290 
 291 
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